{"id":6294,"date":"2024-08-28T06:59:28","date_gmt":"2024-08-28T06:59:28","guid":{"rendered":"https:\/\/mpelembe.net\/?p=6294"},"modified":"2024-09-10T14:33:24","modified_gmt":"2024-09-10T14:33:24","slug":"fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies","status":"publish","type":"post","link":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/","title":{"rendered":"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies"},"content":{"rendered":"

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight\u2122 Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. Continue reading<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its inRead More…<\/a><\/p>\n","protected":false},"author":1,"featured_media":6295,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAowu7GVCw:productID":"","_crdt_document":"","activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":3,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"federate","footnotes":""},"categories":[21],"tags":[5645,12760,12759,12763,12762,1310,12761],"class_list":["post-6294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-reasearch","tag-biomarkers","tag-cancer-biomarker","tag-companion-diagnostic","tag-illumina","tag-illumina-inc","tag-inc","tag-oncology"],"featured_image_src":"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B.jpg","blog_images":{"medium":"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B-300x169.jpg","large":"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B.jpg"},"ams_acf":[],"yoast_head":"\nFDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies - Mpelembe Network<\/title>\n<meta name=\"description\" content=\"TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. The 500+ gene biomarker test advances access to localized precision oncology for patients\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies - Mpelembe Network\" \/>\n<meta property=\"og:description\" content=\"TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. The 500+ gene biomarker test advances access to localized precision oncology for patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Mpelembe Network\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-28T06:59:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-10T14:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#\\\/schema\\\/person\\\/2421ebbf3150931b1066b10a196d7608\"},\"headline\":\"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies\",\"datePublished\":\"2024-08-28T06:59:28+00:00\",\"dateModified\":\"2024-09-10T14:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/\"},\"wordCount\":94,\"image\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mpelembe.net\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/Illumina_16_9_Face_B.jpg\",\"keywords\":[\"Biomarkers\",\"Cancer biomarker\",\"Companion diagnostic\",\"Illumina\",\"Illumina, Inc.\",\"Inc.\",\"Oncology\"],\"articleSection\":[\"Reasearch\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/\",\"url\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/\",\"name\":\"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies - Mpelembe Network\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mpelembe.net\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/Illumina_16_9_Face_B.jpg\",\"datePublished\":\"2024-08-28T06:59:28+00:00\",\"dateModified\":\"2024-09-10T14:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#\\\/schema\\\/person\\\/2421ebbf3150931b1066b10a196d7608\"},\"description\":\"TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. The 500+ gene biomarker test advances access to localized precision oncology for patients\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mpelembe.net\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/Illumina_16_9_Face_B.jpg\",\"contentUrl\":\"https:\\\/\\\/mpelembe.net\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/Illumina_16_9_Face_B.jpg\",\"width\":400,\"height\":225,\"caption\":\"Illumina announced FDA approval of its cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mpelembe.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#website\",\"url\":\"https:\\\/\\\/mpelembe.net\\\/\",\"name\":\"Mpelembe Network\",\"description\":\"Collaboration Platform\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mpelembe.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#\\\/schema\\\/person\\\/2421ebbf3150931b1066b10a196d7608\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/mpelembe.net\"],\"url\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies - Mpelembe Network","description":"TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. The 500+ gene biomarker test advances access to localized precision oncology for patients","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/","og_locale":"en_US","og_type":"article","og_title":"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies - Mpelembe Network","og_description":"TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. The 500+ gene biomarker test advances access to localized precision oncology for patients","og_url":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/","og_site_name":"Mpelembe Network","article_published_time":"2024-08-28T06:59:28+00:00","article_modified_time":"2024-09-10T14:33:24+00:00","og_image":[{"width":400,"height":225,"url":"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/#article","isPartOf":{"@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/"},"author":{"name":"admin","@id":"https:\/\/mpelembe.net\/#\/schema\/person\/2421ebbf3150931b1066b10a196d7608"},"headline":"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies","datePublished":"2024-08-28T06:59:28+00:00","dateModified":"2024-09-10T14:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/"},"wordCount":94,"image":{"@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B.jpg","keywords":["Biomarkers","Cancer biomarker","Companion diagnostic","Illumina","Illumina, Inc.","Inc.","Oncology"],"articleSection":["Reasearch"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/","url":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/","name":"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies - Mpelembe Network","isPartOf":{"@id":"https:\/\/mpelembe.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/#primaryimage"},"image":{"@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B.jpg","datePublished":"2024-08-28T06:59:28+00:00","dateModified":"2024-09-10T14:33:24+00:00","author":{"@id":"https:\/\/mpelembe.net\/#\/schema\/person\/2421ebbf3150931b1066b10a196d7608"},"description":"TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. The 500+ gene biomarker test advances access to localized precision oncology for patients","breadcrumb":{"@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/#primaryimage","url":"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B.jpg","contentUrl":"https:\/\/mpelembe.net\/wp-content\/uploads\/2024\/08\/Illumina_16_9_Face_B.jpg","width":400,"height":225,"caption":"Illumina announced FDA approval of its cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies."},{"@type":"BreadcrumbList","@id":"https:\/\/mpelembe.net\/index.php\/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mpelembe.net\/"},{"@type":"ListItem","position":2,"name":"FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies"}]},{"@type":"WebSite","@id":"https:\/\/mpelembe.net\/#website","url":"https:\/\/mpelembe.net\/","name":"Mpelembe Network","description":"Collaboration Platform","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mpelembe.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/mpelembe.net\/#\/schema\/person\/2421ebbf3150931b1066b10a196d7608","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/mpelembe.net"],"url":"https:\/\/mpelembe.net\/index.php\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/posts\/6294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/comments?post=6294"}],"version-history":[{"count":1,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/posts\/6294\/revisions"}],"predecessor-version":[{"id":6296,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/posts\/6294\/revisions\/6296"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/media\/6295"}],"wp:attachment":[{"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/media?parent=6294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/categories?post=6294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/tags?post=6294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}